Clairvoyant is focused on short path clinical trial speed to market strategy for psilocybin psycho assisted therapy in Canada, the EU and the UK. Our seasoned clinical team has 100 years of drug development experience and was directly responsible for over 20 clinical trials. Clairvoyant is initiated a phase 2b psilocybin therapy clinical trial in Alcohol Use Disorder (AUD) in 2022. Clairvoyant's mission is to provide evidence based-psychedelic therapy to help patients live healthier and enriched lives and build stronger communities.